TABLE 1.

Use of fluconazole to predict ravuconazole susceptibility patterns for 12,796 clinical isolates of Candida spp. from the Global Antifungal Surveillance Program, 1992 to 2002

Species (no. of isolates tested)Fluconazole susceptibility categoryNo. (%) of isolates in ravuconazole category
S (≤1 μg/ml)R (≥2 μg/ml)
All Candida (12,796)S11,656 (91.16)10 (0.1)
S-DD732 (5.7)34 (0.2)
R179 (1.4)185 (1.5)
C. albicans (7,521)S7,441 (98.9)1 (<0.1)
S-DD36 (0.5)1 (<0.1)
R27 (0.3)15 (0.2)
C. glabrata (1,869)S1,218 (65.2)6 (0.3)
S-DD452 (24.2)29 (1.6)
R18 (0.9)146 (7.8)
C. parapsilosis (1,485)S1,435 (96.6)0 (0.0)
S-DD43 (2.9)0 (0.0)
R7 (0.5)0 (0.0)
C. tropicalis (1,185)S1,159 (97.8)1 (0.1)
S-DD6 (0.5)3 (0.3)
R1 (0.1)15 (1.2)
C. krusei (302)S8 (2.7)0 (0.0)
S-DD171 (56.6)1 (0.3)
R120 (39.7)2 (0.7)
C. lusitaniae (128)S124 (96.9)0 (0.0)
S-DD3 (2.3)0 (0.0)
R1 (0.8)0 (0.0)
C. dubliniensis (103)S94 (91.3)0 (0.0)
S-DD6 (5.8)0 (0.0)
R1 (1.0)2 (1.9)
C. guilliermondii (84)S73 (86.9)2 (2.4)
S-DD6 (7.1)0 (0.0)
R0 (0.0)3 (3.6)
C. pellliculosa (34)S34 (100)0 (0.0)
S-DD0 (0.0)0 (0.0)
R0 (0.0)0 (0.0)
C. kefyr (28)S28 (100)0 (0.0)
S-DD0 (0.0)0 (0.0)
R0 (0.0)0 (0.0)
C. rugosa (19)S15 (79)0 (0.0)
S-DD4 (21)0 (0.0)
R0 (0.0)0 (0.0)
C. famata (16)S12 (75)0 (0.0)
S-DD4 (25)0 (0.0)
R0 (0.0)0 (0.0)